Document is current
Any future updates will be listed below
-
Authors
Tanakaya, Kohji https://orcid.org/0000-0001-8901-6911
Yamaguchi, Tatsuro
Hirata, Keiji
Yamada, Masayoshi
Kumamoto, Kensuke
Akiyama, Yasuki
Ishimaru, Kei
Okamoto, Koichi
Kawasaki, Yuko
Komine, Keigo
Sakamoto, Akira
Shigeyasu, Kunitoshi
Shibata, Yoshiko
Shimamoto, Yusaku
Shimodaira, Hideki
Sekine, Shigeki
Takao, Akinari
Takao, Misato
Takamizawa, Yasuyuki
Takeuchi, Yoji
Tanabe, Noriko
Taniguchi, Fumitaka
Chino, Akiko
Cho, Hourin
Doi, Satoru
Nakajima, Takeshi
Nakamori, Sakiko
Nakayama, Yoshiko
Nagasaki, Toshiya
Hasumi, Hisashi
Banno, Kouji
Hinoi, Takao
Fujiyoshi, Kenji
Horimatsu, Takahiro
Masuda, Kenta
Miguchi, Masashi
Mizuuchi, Yusuke
Miyakura, Yasuyuki
Mutoh, Michihiro
Yoshioka, Takahiro
Tanaka, Shinji
Sakamoto, Kazuhiro
Sakamaki, Kentaro
Itabashi, Michio
Ishida, Hideyuki
Tomita, Naohiro
Sugihara, Kenichi
Ajioka, Yoichi
,
-
Funding
Funding for this research was provided by:
Japanese Society for Cancer of the Colon and Rectum
- License Information
-
More Information
Article History
Received: 21 May 2025
Accepted: 22 September 2025
First Online: 10 November 2025
Declarations
:
: All members with the exception of the discussion chair (committee chair) voted in all CQs. None of the committee members reported on economic COIs, determined according to the rules of the JSCCR. Also, none of the commissioners had academic COIs for CQs. Therefore, all of the committee members except the discussion chair voted in all CQs.As a result of the self-reported declarations of conflicts of interest (COI) by the members of the JSCCR HCRC Guideline Committee and the JSCCR Guideline Evaluation Committee, the following companies were disclosed:AstraZeneca K.K., Eisai Co., Ltd., Olympus Corporation, Asahi Kasei Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Taiho pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Amino Up Co., Ltd.
